- In August 2024, ARS Pharmaceuticals launched Neffy, an epinephrine nasal spray approved by the FDA for the treatment of anaphylaxis. Neffy offers a needle-free alternative for individuals at risk of severe allergic reactions, enhancing the accessibility and ease of emergency care
- In October 2023, Otrivin Nasal Mist was introduced using microdroplet technology to provide effective relief for nasal congestion. This product offers a gentle mist for better coverage in the nasal passages, improving patient comfort and ease of use
- In August 2023, Padagis LLC, a leading provider of specialty pharmaceuticals, introduced the first over-the-counter (OTC) Naloxone HCl Nasal Spray in the U.S. This groundbreaking product is designed to quickly reverse the life-threatening effects of opioid overdoses, making it more accessible to the public
- In March 2023, Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd, launched additional strengths of the generic version of Revlimid® (lenalidomide capsules) in 2.5 mg and 20 mg doses in the U.S., aimed at expanding the company’s product portfolio
- In January 2023, Viatris Inc. a global healthcare company, announced the completion of its acquisitions of Oyster Point Pharma and Famy Life Sciences, marking the creation of its new Viatris Eye Care Division. This acquisition is expected to support the company's business expansion efforts
- In November 2021, Amcyte Pharma, a Seattle-based innovative pharmaceutical company, announced the U.S. launch of Nasitrol nasal spray, specifically formulated for sinus irrigation. This product aims to provide relief for sinus congestion and improve nasal health through routine use
- In October 2021, Cipla, Inc. launched Naselin, an antiviral nasal spray designed to protect against respiratory tract infections caused by coronaviruses. This product was developed to offer an additional layer of defense against viral infections, particularly during the COVID-19 pandemic
